Glenmark enters clinic with 'derisked' early stage pain MAb
This article was originally published in Scrip
Glenmark Pharmaceuticals is moving ahead in the UK with the development of GBR-900, its "derisked" first in class monoclonal antibody for chronic pain targeting tyrosine kinase A (TrkA), the receptor of nerve growth factor (NGF).
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…